Stock Events

Stock Events

Canton Strategic 

$2.30
37
-$0.05-1.92% Friday 19:59

Statistics

Day High
2.31
Day Low
2.29
52W High
7.71
52W Low
1.17
Volume
53,113
Avg. Volume
-
Mkt Cap
160.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-2.45
-1.77
-1.1
-0.42
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-35.92MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow THAR. It's not an investment recommendation.
Mercedes-Benz Group
3
MBG.XETRA
iShares Bitcoin Trust Beneficial Interest
3
IBIT
Apple
2
AAPL
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap27.09B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap23.14B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.53B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap104.13B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Show more...
CEO
Mr. Mark Wendland
Employees
2
Country
United States
ISIN
US4327053090

Listings

XNAS
US
THAR
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN

0 Comments

Share your thoughts

FAQ

What is Canton Strategic stock price today?▼
The current price of THAR is $2.30 USD — it has decreased by -1.92% in the past 24 hours. Watch Canton Strategic stock price performance more closely on the chart.
What is Canton Strategic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Canton Strategic stocks are traded under the ticker THAR.
Is Canton Strategic stock price growing?▼
THAR stock has fallen by -3.77% compared to the previous week, the month change is a -31.14% fall, over the last year Canton Strategic has showed a +36.09% increase.
What is Canton Strategic market cap?▼
Today Canton Strategic has the market capitalization of 160.55M
When is the next Canton Strategic earnings date?▼
Canton Strategic is going to release the next earnings report on September 02, 2026.
What is Canton Strategic revenue for the last year?▼
Canton Strategic revenue for the last year amounts to 0 USD.
What is Canton Strategic net income for the last year?▼
THAR net income for the last year is -35.92M USD.
How many employees does Canton Strategic have?▼
As of July 19, 2026, the company has 2 employees.
In which sector is Canton Strategic located?▼
Canton Strategic operates in the Health & Wellness sector.
When did Canton Strategic complete a stock split?▼
The last stock split for Canton Strategic was on May 28, 2024 with a ratio of 1:15.
Where is Canton Strategic headquartered?▼
Canton Strategic is headquartered in Red Bank, United States.